Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2026-03-20 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团第十一届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th Board of Directors 7th meeting of the company, including approval of various reports such as the 2025 President's Work Report, Board Work Report, Independent Directors' Reports, Audit Committee Report, Profit Distribution Plan, Annual Report, Internal Control Evaluation Report, and others. It also includes proposals for financing, asset impairment, cash management, guarantees, appointment of auditors, sustainability report, amendments to company bylaws, and remuneration plans. The document repeatedly states that these reports and announcements are disclosed on the Shanghai Stock Exchange website and other media, indicating this document itself is a meeting resolution announcement rather than the full reports. The document length is 4726 characters, which is relatively short and mainly summarizes decisions and references full reports elsewhere. This fits the profile of a Board/Management Information filing, which covers announcements of board decisions and management matters. It is not the full Annual Report (10-K), nor a simple announcement of report publication (RPA), nor a proxy solicitation or voting results. Therefore, the best classification is MANG (Board/Management Information).
2026-03-20 Chinese
健民集团关于2026年度对外担保额度预计的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 健民药业集团股份有限公司 regarding the provision of guarantees for its controlling subsidiaries. It details the guarantee amounts, the financial status of the subsidiaries, the board's approval, and the necessity and risk control of the guarantees. The document is structured as a formal announcement with tables and financial data related to guarantees but does not contain comprehensive financial statements or detailed financial performance analysis typical of annual or interim reports. It is not a full audit report or earnings release. The content focuses on the update about guarantees provided to subsidiaries, which is a capital/financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is about 5240 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2026-03-20 Chinese
健民集团辛金国独立董事2025年述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of a company, covering the director's professional background, attendance and participation in board and committee meetings, audit supervision, internal control, communication with shareholders, and overall evaluation of the company's governance and compliance during the year 2025. It includes substantive content on corporate governance, audit committee activities, internal controls, financial oversight, and shareholder engagement. The document is lengthy (6412 characters) and contains detailed management and governance information rather than just an announcement or a brief summary. It is not a certification, proxy statement, or voting result announcement. The content aligns with a Management Report or detailed governance and oversight report by a board member, which fits best under the category of Board/Management Information (MANG).
2026-03-20 Chinese
健民集团2025年度可持续发展报告
Environmental & Social Information Classification · 90% confidence The document is clearly titled as the company’s 2025 annual sustainability report (第九份年度可持续发展报告) detailing environmental management, social responsibility, governance structure (ESG management), stakeholder communication, ESG ratings, awards, and related non-financial performance metrics. It is a standalone ESG disclosure rather than a financial report, earnings release, or any management or legal filing. Therefore, it fits the Environmental & Social Information category.
2026-03-20 Chinese
健民集团关于聘任2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the appointment of the audit firm for the fiscal year 2026. It details the proposed audit firm, its qualifications, the audit team, audit fees, and the approval process including board and shareholder meetings. It does not contain any actual audit report or financial statements, but rather informs shareholders and the public about the intention to appoint the audit firm and the related procedures. The document length is relatively short (2275 characters) and it is clearly an announcement, not the audit report itself. Therefore, it fits the category of Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report document itself. However, since it is an announcement of the appointment of the audit firm, it is best classified as Audit Report / Information (AR) rather than Annual Report (10-K) or Report Publication Announcement (RPA). FY 2026
2026-03-20 Chinese
健民集团关于召开2025年年度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling of a 2025 annual performance explanation meeting (业绩说明会) by the company. It specifies the date, time, location, and format of the meeting, and invites investors to participate and ask questions. It also mentions that the 2025 annual report will be published on March 21, 2026, but this document itself is not the annual report or the performance report. The document is short (1533 characters) and serves as a notice for an upcoming investor presentation event rather than containing financial data or detailed results. Therefore, it fits the category of an Investor Presentation announcement or notice. However, since it is an announcement of the meeting rather than the presentation materials themselves, and given the definitions, the best fit is Investor Presentation (IP) because it is about a detailed presentation for investors focusing on financials and strategy, even though the actual presentation will occur later. Confidence is high due to clear meeting details and purpose.
2026-03-16 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.